Table 1. Open phase 2/3 studies for patients with MSI or MMR-d CRC.
| Immune target | Agent | Phase | Line | NCT number |
|---|---|---|---|---|
| PD-1 | mFOLFOX6/bevacizumab + atezolizumab or atezolizumab alone or FOLFOX6/bevacizumab | III | First-line | NCT02997228 |
| Pembrolizumab vs. chemotherapy | III | After first-line | NCT02563002 | |
| MEDI4736 (durvalumab) | II | Refractory | NCT02227667 | |
| Pembrolizumab | II | Refractory | NCT02460198 | |
| Cancer vaccine | DC vaccination | I/II | Any | NCT01885702 |
NCT, national clinical trial; PD-1, programmed cell death-1; FOLFOX6, 5 fluorouracil, leucovorin, oxaliplatin; vs., versus; DC, dendritic cell.